Human skin permeation of Δ8-tetrahydrocannabinol, cannabidiol and cannabinol

Journal of Pharmacy and Pharmacology

Volumn 56, Issue 3, 2004, Pages 291-297

  Stinchcomb, Audra L ^a   Valiveti, Satyanarayana ^a   Hammell, Dana C ^a   Ramsey, Diana R ^a  

^a University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CANNABIDIOL; CANNABINOID DERIVATIVE; CANNABINOL; DELTA8 TETRAHYDROCANNABINOL;

ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DIFFUSION; DRUG PENETRATION; DRUG STRUCTURE; DRUG TISSUE LEVEL; HUMAN; HUMAN TISSUE; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; SKIN PENETRATION; STRUCTURE ANALYSIS; THERMAL ANALYSIS; THERMODYNAMICS; TRANSDERMAL PATCH;

ABDOMEN; CANNABIDIOL; CANNABINOL; DIFFUSION CHAMBERS, CULTURE; HUMANS; PERMEABILITY; SKIN; TETRAHYDROCANNABINOL; TISSUE AND ORGAN HARVESTING;

EID: 1642374850     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357022791     Document Type: Article

References (29)

1. Bornheim, L. M., Kim, K. Y., Li, J., Perotti, B. Y. T., Benet, L. Z. (1995) Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain. Drug Metab. Dispos. 23: 825-831
2. Bronaugh, R. L. (1996) In vitro viable skin model. In: Borchardt, R. T., Smith, P. L., Wilson, G. (eds) Models for Assessing Drug Absorption and Metabolism. Plenum Press, New York, pp 375-385
3. Challapalli, P. V. N., Stinchcomb, A. L. (2002) In vitro experiment optimization for measuring tetrahydrocannabinol skin permeation. Int. J. Pharm. 241: 329-339
4. Consroe, P., Sandyk, R., Snider, S. R. (1986) Open label evaluation of cannabidiol in dystonic movement disorders. Int. J. Neurosci. 30: 277-282
5. Cunha, J. M., Carlini, E. A., Pereira, A. E., Ramos, O. L., Pimentel, C., Gagliardi, R., Sanvito, W. L., Lander, N., Mechoulam, R. (1980) Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21: 175-185
6. Dalton, W. S., Martz, R., Lemberger, L., Rodda, B. E., Forney, R. B. (1976) Influence of cannabidiol on delta-9-tetrahydrocannabinol effects. Clin. Pharmacol. Ther. 19: 300-309
7. Fabin, B., Touitou, E. (1991) Localization of lipophilic molecules penetrating rat skin in vivo by quantitative autoradiography. Int. J. Pharm. 74: 59-65
8. Grinspoon, L., Bakalar, J. B. (1997) Marihuana, the Forbidden Medicine. Yale University Press, New Haven, CT
9. Grotenhermen, F. (2003) Pharmacokinetics and pharmacodynamics of cannabinoids. Clin. Pharmacokinet. 42: 327-360
10. GW Pharmaceuticals (online). Available from URL: http://www.gwpharm.com (accessed 2003 Sep 9)
11. Hildebrand, J. H., Scott, R. L. (1950) The Solubility of Nonelectrolytes. Reinhold Pub. Corp., New York, Chapter 12
12. Hollister, L. E., Gillespie, H. (1975) Interactions in man of delta-9-tetrahydrocannabinol II. Cannabinol and cannabidiol. Clin. Pharmacol. Ther. 18: 80-83
13. Jaeger, W., Benet, L. Z., Bornheim, L. M. (1996) Inhibition of cyclosporine and tetrahydrocannabinol metabolism by cannabidiol in mouse and human microsomes. Xenobiotica 26: 275-284
14. 9-tetrahydrocannabinol in man. Eur. J. Pharmacol. 28: 172-177
15. Karniol, I. G., Shirakawa, I., Takahashi, R. N., Knobel, E., Musty, R. E. (1975) Effects of delta-9-tetrahydrocannabinol and cannabinol in man. Pharmacology 13: 502-512
16. 9-tetrahydrocannabinol in the presence and absence of cannabidiol. Symposium on the Cannabinoids, 2001 Jun 28-30. San Lorenzo de El Escorial, International Cannabinoid Research Society, Burlington, p. 76
17. Mechoulam, R., Shvo, Y. (1963) The structure of cannabidiol. Tetrahedron 19: 2073-2078
18. 9 tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. Life Sci. 63: PL1-6
19. Potts, R. O., Guy, R. H. (1992) Predicting skin permeability. Pharm. Res. 9: 663-669
20. Sandyk, R., Snider, S. R., Consroe, P., Elias, S. M. (1986) Cannabidiol in dystonic movement disorders. Psychiatry Res. 18: 291
21. Scheuplein, R. J., Blank, I. H. (1973) Mechanism of percutaneous absorption IV. Penetration of nonelectrolytes (alcohols) from aqueous solutions and from pure liquids. J. Invest. Dermatol. 60: 286-296
22. Stinchcomb, A. L., Dua, R., Paliwal, A., Woodard, R. W., Flynn, G. L. (1995) A solubility and related physicochemical property comparison of buprenorphine and its 3-alkyl esters. Pharm. Res. 12: 1526-1529
23. Touitou, E., Fabin, B. (1988) Altered skin permeation of a highly lipophilic molecule: Tetrahydrocannabinol. Int. J. Pharm. 43: 17-22
24. Touitou, E., Fabin, B., Dany, S., Almog, S. (1988) Transdermal delivery of tetrahydrocannabinol. Int. J. Pharm. 43: 9-15
25. Vinciguerra, V., Moore, T., Brennan, E. (1988) Inhalation marijuana as an antiemetic for cancer chemotherapy. NY State J. Med. 88: 525-527
26. Weiner, B. (ed.) (1996) Physician's Desk Reference Generics, 2nd edn, Medical Economics, New Jersey, pp 1083-1086
27. Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., Thompson, A. (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomized placebo-controlled trial. Lancet 362: 1517-1526
28. 9-THC in normal subjects. Psychopharmacology (Berl.) 76: 245-250
29. Zuardi, A. W., Morais, S. L., Guimarães, F. S., Mechoulam, R. (1995) Antipsychotic effect of cannabidiol. J. Clin. Psychiatry 56: 485-486